Skip to main content

2014 Canadian Guidelines for AF Management: Part 1: Introduction and CCS “CHADS-65” Algorithm

by Ian Stiell MD @EMO_Daddy














In this and subsequent postings we will discuss the latest recommendations for ED management of atrial fibrillation (AF) as presented in the newly published 2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. The Guidelines PDF can be downloaded from the CCS website at 2014 Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation

The 2014 Focused Update uses the GRADE system of evidence evaluation as was the case in the comprehensive 2010 AF Guidelines and the 2012 Update. The CCS AF Guidelines Panel is comprised of Canadian cardiologists plus physicians from internal medicine, family medicine, neurology, and emergency medicine. This 2014 Update provides evidence review and recommendations for 8 aspects of AF care, including ED Management (written by myself and Dr. Laurent Macle of the Montreal Heart Institute). The 2014 Update focuses on advances in oral anticoagulant (OAC) therapy and presents a new “CCS Algorithm” (Figure 1) that will help physicians determine the need for anticoagulation, regardless of whether seen in the office or the ED.
For ED physicians, this new algorithm changes the paradigm of our obligation to ensure that AF patients are adequately protected from the risk of stroke. Particularly for recent-onset AF cases where we choose electrical or pharmacological cardioversion, we should consider the indications for prescribing anti-thrombotic therapy on discharge. Oral anticoagulants are now recommended for all AF patients aged 65 or older or who have any one of the traditional CHADS2 risk factors of stroke, hypertension, heart failure, or diabetes (remember as CHADS-65).  Otherwise, patients with a history of coronary artery disease or arterial vascular disease should be prescribed ASA. CCS recommends that the first choice for oral anticoagulation should be the novel direct-acting OACs, i.e. NOACs, for non-valvular AF. The big paradigm change is that ED physicians should prescribe OACs to at-risk AF patients before they leave the ED.
In the next posting, Part 2, we will look at the updated ED AF Management Algorithm that stratifies patients by their hemodynamic stability as well as their immediate risk of stroke.

Specific GRADE Recommendations #1-7 for Anticoagulation

Let us know your thoughts and comments here or on Twitter @EMO_Daddy or @emergmedottawa

Comments

  1. Just confused with European guidelines suggesting INCREASED risk with ASA monotherapy in AF patients.

    ReplyDelete
  2. Can you clarify your comment? What guidelines are you referring to and increased risk of what with ASA (bleeding, embolic events, etc?)? Thanks!

    ReplyDelete
  3. Summary of Summary:

    Unstable / A.Fib <48hrs / >3wks Therap. OAC: Cardiovert + D/C w/ OAC + Cardio.F/U

    A.Fib >48hrs or <3wks of Therap. OAC: Rate ctrl (<100: BB/CCB) + F/U w/ Cardio.

    OAC choice based on CHADS2 (w/ Age >= 65):
    - 1+ = NOAC > Warfarin or (ASA+Plavix)
    - 0+CAD = ASA
    - 0 = nothing

    If Valvular AF (Mechanical valve / Hx Rheumatic MS): Warfarin > NOAC

    ReplyDelete

Post a Comment

Popular posts from this blog

Tips for Success in your Emergency Medicine Rotation

Our wonderful medical students are preparing to start their first clinical rotations. With this in mind here are some of the top tips for success in your EM rotation
1)Be On Time – show up to your shifts on time, better yet 5 minutes early.That first impression is immensely important.
2)Introduce yourself to the team - “Hi my name is John Doe, I am the medical student on shift today” introduce yourself to the attending, residents, nurses, etc.You will be called on a lot more to help when there is something interesting going on if they know your name.
3)Be goal-oriented – have a goal for each shift, whether it’s a procedure or a type of presentation to see.
4)Don’t just stand there, do something – whenever there is a trauma or code, come to the bedside.Get gowned up for traumas and pay attention.Help with things that are within your scope of practice: chest compressions, moving patient, cardioversion
5)Don’t just stand there, do nothing – there are times in medicine when the best thing to d…

You CAN reverse that! Reversal of NOAC's and more..

We have seen a large surge of the utilization of New Oral Anticoagulants (NOAC's) in the past few years, as such, it has been a novel challenge when these patients present to the Emergency Department (ED) with life threatening bleeding. Dr. Michael Ho looks to discuss treatment options, and future options in these patients. 
NOACs vs WarfarinDabigatran, Rivaroxaban and Apixaban have seen a dramatic increase in use since their approval in Canada. Dabigatran is a direct thrombin (Factor II) inhibitor, while the latter two are direct Xa inhibitors. These drugs are collectively referred to as novel oral anticoagulants (NOACs). They have also been called direct, or target-specific oral anticoagulants (DOACs or TSOACs) [1]. 
The NOACs have many practical advantages over warfarin: Rapid onset of actionShorter half-lifeLess food and drug interferencePredictable pharmacokineticsEase of use and no requirement for monitoringThe downsides to NOACs are the higher cost to the patient, the inabilit…